Visiox Pharma LLC

Plus, news on the Immunome-Atreca asset deal, Cyclo Therapeutics’ reverse merger, Nestlé buying CDX-7108 from Codexis, Oncternal, Visiox and more. So long, Applied Molecular Transport: The stock symbol $AMTI officially became history as Cyclo Therapeutics completed its reverse merger and took Applied Molecular Transport’s spot on the Nasdaq under the ticker $CYTH . Applied Molecular Transport began hunting for strategic alternatives in late March after it halted all R&D activities and laid off the bulk of its staff in the wake of a Phase II flop in ulcerative colitis. The deal with Cyclo was announced in September. The company will now focus on a Phase III study of its reformulated drug for Niemann-Pick Disease Type C1. — Amber Tong

OSAKA, Japan--(BUSINESS WIRE)-- Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®. Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®. Santen has also made an asset transfer agreement with Harrow Health, Inc. (Nasdaq: HROW, hereafter Harrow Health) for Flarex® (an eyedrop for ocular surface Inflammation associated with dry eye), Natacyn® (an eyedrop for fungal blepharitis, conjunctivitis, and keratitis), TobraDex® ST (an eyedrop for ocular inflammation with presence of risk of infection), ZERVIATE® (an eyedrop for ocular itch associated with allergic conjunctivitis), FRESHKOTE® (an eyedrop for temporary relief of symptoms of dry eye) and an out-licensing agreement on the rights for product manufacturing, commercialization, and sales of Verkazia® (an eyedrop for vernal keratoconjunctivitis) and Cationorm® Plus (an artificial tear). Under the terms of the agreement, Santen will sell and transfer Flarex®, Natacyn®, TobraDex® ST, ZERVIATE®, and FRESHKOTE® and grant Harrow Health exclusive rights in the U.S. and Canada for product manufacturing and commercialization of Verkazia®, and exclusive rights in Canada for product manufacturing and commercialization of Cationorm® Plus. Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus. Santen will continue to strive to improve profitability from a company-wide perspective, secure investment in research and development that serves unmet medical needs, and further promote the development of a promising pipeline to maximize its contribution to patients. About Santen As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in more than 60 countries and regions. Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website ( ). View source version on businesswire.com: Contacts Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: communication@santen.com Source: Santen Pharmaceutical Co., Ltd. View this news release online at:

TARRYTOWN, N.Y., Dec. 8, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2023. "The NDA acceptance for filing is an exciting milestone and an important next step towards the planned approval and commercial launch of PDP-716," said Ryan Bleeks, Chief Executive Officer. "If approved, Visiox has the potential to bring the first once-daily brimonidine to market for the treatment of glaucoma to patients and eye care professionals." About Visiox Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. Visiox plans to soon submit a second New Drug Application for SDN-037 to the U.S. FDA to address an unmet need for cataract surgery. SDN-037 is a twice daily topical difluprednate corticosteroid utilizing patented TJMTM (Tight Junction Modulation) proprietary formulation. The novel technology provides powerful post-surgical control of inflammation in a clear solution enabling convenient dosing with a proven active ingredient. Cataract extraction is the most frequently performed eye surgery in the U.S. It accounts for 70% of all ocular surgeries. 50 million people are projected to have cataracts in the U.S. by 20501. PDP-716, SDN-037, and TearActTM delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd. For more information, please visit Visiox Pharma or LinkedIn.